InspireMD, Inc.

Overview

1. "How the company got here" InspireMD, Inc. was founded in 2005 and is a medical device company focused on creating solutions to prevent strokes and treat vascular conditions. The company's journey has involved developing proprietary technology, such as its MicroNet™ mesh, which is a key component in its product offerings. A significant turning point was the U.S. Food and Drug Administration (FDA) approval of its CGuard Prime Carotid Stent System in June 2025, which was based on strong clinical trial results demonstrating low rates of major adverse events. This approval paved the way for the company to launch its product in the United States, a crucial market for its growth. InspireMD has also strategically moved its global headquarters to Miami, Florida, to better support its U.S. market expansion. 2. "What it actually does" InspireMD develops and sells medical devices designed to prevent strokes, particularly those related to carotid artery disease. Their main technology involves a special mesh material called MicroNet™, which is used in their stent systems. This mesh is designed to act as a barrier within blood vessels, preventing plaque (fatty buildup) from breaking off and traveling to the brain, which can cause a stroke. The company's products are used by healthcare professionals, such as surgeons and interventional cardiologists, to treat patients with narrowed or diseased arteries. 3. "CGuard Carotid Embolic Prevention System" The CGuard Carotid Embolic Prevention System (EPS) is InspireMD's primary product line and the main way the company makes money. This system includes a stent, which is a small mesh tube used to open up narrowed arteries, combined with the MicroNet™ mesh. The MicroNet™ mesh is designed to trap plaque and other debris within the artery, preventing them from dislodging and causing a stroke. This technology is specifically used to treat carotid artery disease, a condition where the arteries supplying blood to the brain become narrowed. The CGuard system has received regulatory approval in Europe and, more recently, in the United States, allowing the company to sell it to hospitals and clinics. This segment represents the vast majority of InspireMD's revenue. 4. "What management is betting on now" InspireMD's management is focused on expanding the commercialization of its CGuard Prime Carotid Stent System, particularly in the U.S. market. A key strategic priority is obtaining further regulatory approvals for new indications and enhanced delivery systems, such as for Transcarotid Artery Revascularization (TCAR) procedures, which could significantly increase the company's addressable market. Management is also investing in clinical trials to gather more evidence supporting the effectiveness and safety of their products. They are working to scale up operations, including manufacturing, to meet anticipated demand and are focused on improving operational efficiency and cost structure to support growth. The company aims to establish its MicroNet technology as the standard of care in carotid intervention.